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BAckground: Invasive Aspergillosis(IA) is a serious invasive fungal 
infection(IFI), usually affecting immunocomprised patients. In the Netherlands, 
voriconazole(VOR) is the recommended primary targeted antifungal agent and is 
used for the vast majority of IA patients. After unsuccessful first line treatment 
with VOR, Caspofungin(CASP) and liposomal amphotericin B(L-AMB) are two most 
commonly used agents. In a previously published study, CASP was dominant over 
L-AMB, as a targeted salvage antifungal therapy option after VOR for IA treatment 
in the Netherlands. However, trial data used as input might not reflect the real 
world effectiveness of treatment strategies. oBjectives: The objective of this 
study is to conduct a cost-effectiveness analysis of the most common targeted 
antifungal treatment sequences for IA in the Netherlands, using real-world data 
from a national registry. Methods: A previously developed decision analytical 
model was adapted to carry out the cost-effectiveness analysis that compares 
L-AMB vs. CASP as a 2nd line treatment strategy after unsuccessful treatment 
with VOR. Findings from the analysis of the national patient registry informed the 
model structure, treatment patterns, duration/dosage of treatments, events and 
their probabilities. The model estimates both survival during infectious disease 
episode as well as life years saved(LYS) after short-term survival. Extensive sensi-
tivity analyses were conducted to assess the robustness of the results. results: 
Short term survival, life expectancy and cost outcomes for using L-AMB and CASP 
in the 2ndline seem to be similar, after an unsuccessful primary therapy with 
VOR. There is a slight benefit in terms of LYS and costs for L-AMB. The analysis 
results are sensitive to statistical uncertainty due to the low number of patients 
in the registry. conclusions: An updated analysis after more data is collected 
would strengthen reliability/validity of the analysis, and would make it feasible 
to apply statistical matching Methods to adjust for possible confounding by treat-
ment choice.
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oBjectives: Rapid advances in the development of direct-acting antivirals (DAAs) 
have shifted the challenge of treating chronic hepatitis C virus (HCV) from a medical 
challenge to a socioeconomic issue of affordability. A 12-week course of all-oral DAA 
costs approximately USD 84,000. To date, no study has been conducted to determine 
the cost-effectiveness of various DAAs within an Asian context. Methods: We per-
formed a Markov model to simulate a cohort of 50 year-old HCV infected patients 
through 14 treatment strategies over life-time period. Treatment effects including 
sustained virological response and adverse events including anemia, neutropenia and 
thrombocytopenia were derived from published trials. Costs were obtained from a ter-
tiary hospital in Singapore. Subset analysis was conducted to incorporate the implica-
tion of retreatment that reflected real-life situation. results: Using response-guided 
boceprevir (BOC/RGT, least costly treatment) as a base-case, peginterferon/ribavirin, 
48-week boceprevir and genotype-guided therapies were dominated by BOC/RGT as 
they were more costly and less effective. Using the Singapore gross domestic product 
of USD 52,500 as the threshold, 12 weeks of Viekira Pak (ombitasvir/paritaprevir/rito-
navir/dasabuvir) and sofosbuvir/ledipasvir were cost-effective and marginally cost-
effective respectively. Other all-oral DAAs were either dominated by Viekira Pak or 
sofosbuvir/ledipasvir. Roadmap therapy using rapid virologic-response to guide use of 
boceprevir and sofosbuvir was associated with favourable incremental cost per qual-
ity-adjusted life year gained (USD 16,130). BOC/RGT and roadmap therapy remained 
as cost-effective treatment options by incorporating retreatment. conclusions: 
HCV management can be optimised by adopting value-based treatment algorithm 
such as roadmap therapy that offers best value for money.
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oBjectives: Streptococcus pneumonia causes a number of clinical conditions, 
including pneumonia, meningitis, bacteremia, sepsis, and acute otitis media (AOM). 
The objective of this study is to estimate the potential effectiveness and cost-effec-
tiveness of vaccinating infants with the pneumococcal non-typeable Haemophilus 
influenzae Protein D conjugate vaccine (PHiD-CV) compared to the 13-valent pneu-
mococcal conjugate vaccine (PCV-13) in Croatia. These vaccines are currently avail-
able only for risk groups and on private market with a limited uptake, representing 
less than 10% of annual birth cohort. Methods: A Markov cohort model with a 
starting birth cohort of 39,939 infants and a 100-year time horizon was used to 
project the impact of vaccination on the incidence of pneumococcal diseases. In 
the model, individuals move between mutually-exclusive health states and direct 
treatment costs and quality-adjusted life years (QALYs) are aggregated and dis-
counted (3%) in monthly cycles. Vaccine regimen was 2+1 schedule with doses given 
at 2, 4, and 13 months for both vaccines. results: Under our model assumptions 
and assuming both vaccines have the same price, PHiD-CV is predicted to save 
both 13 QALYs and € 138,564 compared to PCV-13 (dominant intervention). Both 
vaccines would prevent about the same numbers of IPD and pneumonia whereas 
PHiD-CV would save more GP visits and clinical interventions related to AOM. If the 
model further accounts for the difference in list price between the two vaccines, 
then vaccinating Croatian infants with PHiD-CV would save a total of € 1,192,753 
compared to PCV-13. Parameters infuencing the most model results are related to 
AOM management (e.g. percentage reduction in myringotomy and disutility for 
outpatient AOM). conclusions: Our results show PHiD-CV dominates PCV-13 in 
most scenarios due to incremental benefits in AOM. Vaccinating with PHiD-CV in 
Croatia could save a substantial health care budget.
of male patients. Total costs (direct medical cost, indirect cost) and quality-adjusted 
life-year (QALY) loss for post-biopsy infection care were outcomes of analysis. Model 
inputs were retrieved from clinical studies published in literature. Sensitivity analysis 
was conducted to examine robustness of model results. results: The base-case 
analysis found rectal culture-guided strategy to be less costly (expected cost HKD1,268 
versus HKD1,633) (USD1= HKD7.8) with lower QALY loss (0.00055 QALY vs 0.00084 
QALY) when compared to empirical strategy. Sensitivity analysis showed that the 
total cost of rectal culture-guided arm would become higher than the empirical arm 
if the effectiveness of rectal culture-guided strategy in reducing post-biopsy infec-
tion was less than 12.07%, or if post-biopsy infection rate of empirical strategy was 
lower than 3.18%. In 10,000 Monte Carlo simulations, rectal culture-guided arm was 
the preferred option in 98.67% of cases with mean total cost saving of HKD449 per 
patient (95%CI HKD443–455; p < 0.001) and lower mean QALY loss of 0.000335 QALYs 
per patient (95%CI 0.000332–0.000338 QALYs; p < 0.001). conclusions: Comparing 
with empirical antibiotic prophylaxis, the use of rectal swab culture to guide the 
choice of antibiotic prophylaxis seems to be a cost-saving and effective intervention 
in men undergoing TRUSBx in Hong Kong.
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oBjectives: Chronic hepatitis C virus (HCV) is a considerable public health concern 
due to its significant impact on morbidity, mortality and healthcare costs. Treatment 
of HCV genotype 1 (GT1)-infected patients with ombitasvir/paritaprevir/ritonavir and 
dasabuvir with or without ribavirin (OBV/PTV/r/DSV±R) demonstrated significantly 
high sustained viral response (SVR) rates and negligible adverse events in clinical 
studies. This study evaluated the cost per SVR for OBV/PTV/r/DSV±R compared to 
sofosbuvir in combination with daclatasvir (SOF+DCV) or simeprevir (SOF+SIM) in 
HCV treatment-naïve patients with GT1 for The Netherlands. Methods: An eco-
nomic evaluation comparing OBV/PTV/r/DSV±R to SOF+DCV or SOF+SIM in terms of 
costs per SVR was performed from the Dutch societal perspective. A Markov model 
with a lifetime time horizon was developed based on previous published models in 
HCV. Transition probabilities, resource use and costs for reference year 2014 were 
derived from the literature, publically available sources and expert opinion. SVR rates 
for all therapies were derived from published literature. Baseline characteristics (e.g., 
age, fibrosis distribution) were based on the OBV/PTV/r/DSV±R trials. results: In 
treatment-naïve HCV GT1 patients, the overall trial SVR rate for OBV/PTV/r/DSV±R 
was 97% (688/708), 98% (124/126) for SOF+DCV and 89% (17/19) for SOF+SIM. Total 
costs were lower for OBV/PTV/r/DSV±R (€ 55,864) compared to SOF+DCV (€ 83,679) 
and SOF+SIM (€ 81,746). Total costs per SVR were also lower for OBV/PTV/r/DSV±R 
(€ 57,592) compared to SOF+DCV (€ 85,387) and SOF+SIM (€ 91,849). Treatment with 
OBV/PTV/r/DSV±R resulted in a cost-savings of € 27,795 and € 34,257 per responding 
patient compared to SOF+DCV and SOF+SIM, respectively. conclusions: Total costs 
per successfully treated treatment-naïve HCV GT1 patient with OBV/PTV/r/DSV±R 
are lower compared to sofosbuvir in combination daclatasvir or simeprevir for the 
Dutch society. Treatment with OBV/PTV/r/DSV±R would lead to cost-savings and thus 
improve the overall budget impact of HCV in the Netherlands.
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oBjectives: To assess cost-effectiveness of voriconazole compared to other medi-
cations recommended in Russia for treatment of invasive aspergillosis (IA) in 
adults. Methods: We developed «decision tree» model, comparing 3 alternative 
first-line therapies in IA: 1) voriconazole, 2), caspofungin, or 3) amphotericin B lipid 
complex (LC). Efficacy was assessed as the probability of patient survival within 14 
weeks of starting treatment. Transition probabilities were calculated on the basis 
of data derived from published clinical research on IA treatment. Costs were cal-
culated as the sum of drugs cost (based on prices in public procurement) and cost 
of prolonged stay in hospital due to serious adverse events (based on the average 
bed-day cost in public health care). In additional model, conventional ampho-
tericin B instead of its LC was administered. Probabilistic sensitivity analysis was 
performed for both models. Costs were converted to EUROs using the average 
weighted exchange rate in 2014 (1€ = 50.815RUR). results: In the base case model 
voriconazole was a dominant strategy for IA treatment (per patient survival 0.742 
and cost € 10,556) in comparison with caspofungin (0.652 and € 17,272, respectively) 
and amphotericin B lipid complex (0.719 and € 34,441). Probabilistic sensitivity 
analysis (1000 simulations) showed the robustness of results. In additional model 
the willingness-to-pay threshold, at which voriconazole had more chances to 
be considered cost-effective in comparison with conventional amphotericine B 
varied from € 984 to € 21,647 per life saved, depending on the choice of second 
line therapy. conclusions: Voriconazole was shown to be either dominant or 
cost-effective strategy for treatment of IA in comparison with other therapies 
recommended in Russian practice.
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